异形性非乳腺细胞血管:来自全球专家的治疗见解
Sandra C Christiansen1, Bruce L Zuraw1
1From the Division of Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, California and.
Allergy and asthma proceedings
|December 31, 2024
概括
异形性非巨细胞血管 (INMA) 专家医生将伊卡蒂班特列为最有效的按需治疗. 在INMA患者的长期预防中,抗纤维解药和兰德鲁马布被评为最有效.
科学领域:
- 免疫学 免疫学 免疫学
- 过敏 过敏是一种过敏.
- 药理学 药理学是指药理学的学科.
背景情况:
- 异常性非细胞血管 (INMA) 是一种罕见的疾病,会引起反复的胀,并可能导致严重的并发症.
- 虽然遗传性血管 (HAE) 的治疗方法用于INMA,但它们的疗效仍然不太清楚.
研究的目的:
- 收集全球专家关于按需治疗 (ODT) 和长期预防 (LTP) 治疗INMA的疗效的意见.
- 根据专家评估,对各种治疗方案的有效性进行排名.
主要方法:
- 一项调查分发给国际专家,专门从事血管.
- 专家使用利克特尺度对INMA的ODT和LTP的疗效进行了评价.
- 分析了24名专家治疗300名INMA患者的数据.
主要成果:
- 46.2%的专家认为伊卡提班对ODT具有高度有效性.
- 抗纤维蛋白解毒剂 (23.1%的高疗效) 和拉纳德鲁马布 (21%的高疗效) 被列为最有效的LTP.
- 其他治疗方法,如血衍生C1抑制剂,皮下C1抑制剂,孕激素和贝罗特拉斯塔也显示了不同程度的预防作用.
结论:
- 在接受调查的专家中,伊卡蒂班被认为是INMA最有效的ODT.
- 根据专家排名,抗纤维素分析药物和lanadelumab是INMA首选的LTP.
- 需要进一步的研究来确定预防性治疗的最终建议.
更多相关视频
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
133
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
133
Open Angle Glaucoma: Treatment
391
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
391
Esophageal Varices-II: Clinical Features and Management
46
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
46
Allergic Reactions
27.2K
Overview
27.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135


